8-K: Neumora Therapeutics' Navacaprant Fails to Meet Primary Endpoint in Phase 3 Depression Trial, Shows Promise in Female Subgroup

Neumora Therapeutics' Phase 3 KOASTAL-1 study of navacaprant for major depressive disorder did not achieve statistical significance on its primary endpoint, though it showed an efficacy signal in female participants.

Summary

• Neumora Therapeutics announced the results of its Phase 3 KOASTAL-1 study for navacaprant in treating major depressive disorder (MDD).
• The study did not demonstrate a statistically significant improvement in depressive symptoms compared to placebo, as measured by the MADRS total score at week 6.
• However, navacaprant showed an efficacy signal in female participants, with a statistically significant improvement in the SHAPS scale.
• The drug was generally well-tolerated, with a safety profile comparable to placebo.
• Neumora plans to further analyze the results and will provide updates at the J.P. Morgan Healthcare Conference on January 14th.
• The company has a cash balance of $342 million as of the end of the third quarter, providing runway into mid-2026.

Sentiment

Score: 4

Explanation: The document reports a failure to meet the primary endpoint in a Phase 3 trial, which is a significant negative. However, there are some positive aspects, such as the efficacy signal in the female subgroup and the strong cash position, which prevents a lower score.

Positives

• Navacaprant showed a statistically significant improvement in the SHAPS scale in female participants.
• The drug was generally well-tolerated with a safety profile comparable to placebo.
• There was no signal for increased suicidal ideation or suicidal behavior compared to placebo.
• Neumora has a strong financial position with $342 million in cash, providing runway into mid-2026.
• A significant proportion of patients who completed the study elected to enroll in the long term extension study.

Negatives

• The KOASTAL-1 study did not meet its primary endpoint of statistically significant improvement in MADRS total score compared to placebo.
• The overall results were not consistent with the body of evidence supporting the mechanism of action in MDD.
• The study showed a lack of efficacy in the male subgroup.

Risks

• The failure to meet the primary endpoint in the KOASTAL-1 study raises concerns about the efficacy of navacaprant for MDD.
• The company faces the risk of not obtaining regulatory approvals for navacaprant.
• There are risks related to the inherent uncertainty of clinical drug development.
• The company relies on third parties, including CROs, which introduces operational risks.
• There are risks related to serious or undesirable side effects of the therapeutic candidates.
• The company faces risks related to its ability to utilize and protect its intellectual property rights.
• There are risks related to the sufficiency of capital resources to fund operations.

Future Outlook

Neumora plans to further analyze the KOASTAL-1 study data, particularly the differences in drug and placebo responses between male and female participants, and will provide updates at the J.P. Morgan Healthcare Conference. The company is continuing with the KOASTAL-2, KOASTAL-3 and KOASTAL-LT studies.

Management Comments

• Rob Lenz, executive vice president, head of research and development, stated that they are disappointed by the results from KOASTAL-1 as they were not consistent with the body of evidence supporting this mechanism in MDD.
• Rob Lenz also mentioned that there is a lot to investigate from this study, in particular the contrast in drug and placebo responses in depressed mood and anhedonia in female participants compared to male participants.
• Henry Gosebruch, president and chief executive officer, said that the outcome of KOASTAL-1 is not what they expected, but there are encouraging trends in the data that they are analyzing.
• Henry Gosebruch also stated that their strong financial foundation and cash balance of $342 million provides runway into mid-2026.

Industry Context

The results of the KOASTAL-1 study highlight the challenges in developing effective treatments for major depressive disorder, a condition with a high unmet need. The focus on novel mechanisms of action, such as the kappa opioid receptor, reflects a broader trend in neuroscience drug development to explore new pathways for treating complex brain diseases. The mixed results, with a signal in the female subgroup, may lead to further research into personalized medicine approaches for depression.

Comparison to Industry Standards

• The failure of navacaprant to meet its primary endpoint in the overall population is a setback, as many Phase 3 trials in depression aim for statistically significant improvements over placebo.
• The efficacy signal in the female subgroup is notable, as it suggests a potential for personalized medicine approaches, which is a growing area of interest in the pharmaceutical industry.
• The safety profile of navacaprant being comparable to placebo is a positive, as many existing antidepressants have significant side effects.
• Companies like Sage Therapeutics and Axsome Therapeutics have had success with novel mechanisms of action in depression, but also have faced challenges in clinical trials, highlighting the difficulty in this area.
• The ongoing KOASTAL-2 and KOASTAL-3 studies will be critical in determining the overall potential of navacaprant, as the results of a single trial are not always conclusive.

Stakeholder Impact

• Shareholders may react negatively to the news of the failed primary endpoint.
• Patients with MDD may be disappointed by the lack of overall efficacy, but the signal in the female subgroup may offer some hope.
• Employees may be concerned about the future of the navacaprant program.
• The company's financial position remains strong, which is a positive for all stakeholders.

Next Steps

• Neumora will further analyze the data from the KOASTAL-1 study.
• The company will provide additional updates on the navacaprant development program at the J.P. Morgan Healthcare Conference on January 14th.
• The KOASTAL-2, KOASTAL-3, and KOASTAL-LT studies are ongoing.

Key Dates

Keywords

navacaprant, major depressive disorder, MDD, KOASTAL-1, clinical trial, Phase 3, kappa opioid receptor antagonist, neuroscience, biopharmaceutical, depression, MADRS, SHAPS